Old and new drugs in systemic therapy of pancreatic cancer

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 2, 2004, Pages 135-151

  Pasetto, Lara Maria ^a   Jirillo, Antonio ^a   Stefani, Micaela ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Pancreatic cancer; Review

Indexed keywords

2,3,5 TRIMETHYL 6 (3 PYRIDYLMETHYL) 1,4 BENZOQUINONE; AMONAFIDE; ANTINEOPLASTIC AGENT; BATIMASTAT; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DEOXYCYTIDINE; DIAZIQUONE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPROPLATIN; IRINOTECAN; LONAFARNIB; METALLOPROTEINASE INHIBITOR; MITOMYCIN C; PROCARBAZINE; RALTITREXED; RAS PROTEIN; STREPTOZOCIN; TIPIFARNIB; TRIMETREXATE; UFT; UNINDEXED DRUG;

ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; MORBIDITY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; RADIATION DOSE; RADIATION INJURY; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURGICAL MORTALITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0842285403     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00170-7     Document Type: Review

References (137)

1. Janes R.H., Niederhuber J.E., Chmiel J.S.et al. National pattern of care for pancreatic cancer: results of a survey by the commission on cancer. Ann. Surg. 223:1996;261-272.
2. Scheithauer W., Pfeffel F., Kornek G., Marczell A., Wiltschke C., Funovics J. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2-interferon in advanced adenocarcinoma of pancreas. Cancer. 70:1992;1864-1866.
3. Rosvold E., Schider R., Walczak J.et al. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chem. Pharm. 29:1992;305-308.
4. Crown J., Casper E.S., Botet J., Murray P., Kelsen D.P. Lack of efficacy of high dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. 9:1991;1682-1684.
5. Bakkevold K.E., Arnesjo B., Dahl O., Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective randomized multicenter study. Eur. J. Cancer. 29A:1993;698-703.
6. Cullinan S.A., Moertel C.G., Fleming T.R.et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 253(14):1985;2061-2067.
7. Amano H., Takada T., Kato H.et al. Five year results of a randomized study of postoperative adjuvant chemotherapy for resected pancreatic biliary carcinomas. Proc. Am. Soc. Clin. Oncol. 18:1999;273. [abstract 1049].
8. Kalser M.H., Ellenberg S.S. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Arch. Surg. 120:1985;899.
9. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection for pancreatic cancer. Cancer 1987;59:2006-10.
10. Douglass H.O., Stablein D.M., Thomas P.R.M. An organized multi-institutional interdisciplinary evaluation of the role of radiation therapy alone or combined with chemotherapy in treatment of adenocarcinoma of the gastrointestinal tract. NCI Monogr. 6:1988;253-257.
11. Klinkenbijl J.H.G., Sahmoud T., Van Pel R. Radiotherapy and 5FU after curative resection for cancer of the pancreas and periampullar region: a phase III trial of the EORTC and GITCCG. Eur. J. Cancer. 33:1997;1239.
12. Klinkenbijl J.H.G., Jeekel J., Sahmoud T.et al. Adjuvant radiotherapy and 5FU after curative resection for cancer of the pancreas and periampullar region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann. Surg. 230:1999;776-784.
13. Chakravarthy A., Abrams R.A., Yeo C.J.et al. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int. J. Radiat. Oncol. Biol. Phys. 48(5):2000;1089-1096.
14. Neoptolemos J.P., Moffitt D.D., Dunn J.A.et al. ESPAC-1: a European, randomized study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. Eur. J. Cancer. 37(suppl 6):2001;253. [abstract 940].
15. Neoptolemos J.P., Dunn J.A., Stocken D.D.et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358(9293):2001;1576-1585.
16. Mehta V.K., Fisher G.A., Ford J.M.et al. Adjuvant radiotherapy and concomitant 5 fluorouracil by protracted venous infusion for resected pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 48(5):2000;1483-1487.
17. Rich T.A. Chemoradiation for pancreatic and biliary cancer: current status of RTOG studies. Ann. Oncol. 10(4):1999;231-233.
18. Nukui Y., Picozzi V.J., Traverso L.W. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg. 179:2000;367-371.
19. Kachnic L.A., Mornex F., Partensky C.et al. Phase II trial of twice-weekly gemcitabine and concurrent radiation for the treatment of resected pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;146b. [abstract 2334].
20. Allen A.M., Zalupski M.M., Eckhauser F.E.et al. A phase I trial of radiation (RT) dose escalation with concurrent full dose gemcitabine following resection of pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;138a. [abstract 549].
21. Neoptolemos J.P., Stocken D.D., Dunn J.A.et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomised controlled trial. Ann. Surg. 234:2001;758-768.
22. Neoptolemos J.P., Raraty M.G., Ghaneh P.et al. Adjuvant and additive therapy for cancer of the pancreas. Chirurg. 74(3):2003;191-201.
23. Abrams R.A., Lillemoe K.D., Plantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 358:2001;1565-1566.
24. Abrams R.A., Grochow L.B., Chakravarthly A.et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and Ca 19-9 levels. Int. J. Rad. Oncol. Biol. Phys. 44:1999;1039-1046.
25. Neoptolemos J.P., Cunningham D., Friess H.et al. Adjuvant therapy in pancreatic cancer: historical and current perspective. Ann. Oncol. 14(5):2003;675-692.
26. Coia L., Hoffman J., Scher R.et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;161-167.
27. Miller A.R., Robinson E.K., Lee J.E.et al. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg. Oncol. Clin. N. Am. 7:1998;183-197.
28. Staley C.A., Lee J.E., Cleary K.R.et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am. J. Surg. 171:1996;118-125.
29. Spitz F.R., Abbruzzese J.L., Lee J.E.et al. Preoperative and postoperative chemoradiation strategies in patients with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol. 15:1997;928-937.
30. Pisters P.W.T., Abbruzzese J.L., Janjan N.A.et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J. Clin. Oncol. 16:1998;3843-3850.
31. Evans D.B., Rich T.A., Byrd D.R.et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg. 127(11):1992;1335-1339.
32. Rich T.A. Chemoradiation or accelerated fractioned: basic considerations. J. Infusional Chemother. 1:1992;2-8.
33. Haustermans K. Neoadjuvant radiotherapy: drugs or rays? Hypo- or hyper-? Eur. J. Cancer. 37(suppl 6):2001;254. [abstract 942].
34. Pisters P.W., Wolff R.A., Janjan N.A.et al. Preoperative paclitaxel and concurrent rapid fractioned radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rate, and event-free outcome. J. Clin. Oncol. 20(10):2002;2537-2544.
35. Breslin T.M., Hess K.R., Harbison D.B.et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol. 8:2001;123-132.
36. Snady H., Bruckner H., Cooperman A., Paradiso H., Kiefer L. Outcomes trial demonstrating a survival advantage of initial chemoradiotherapy for regional pancreatic adenocarcinoma (PCa). Eur. J. Cancer. 37(suppl 6):2001;253. [abstract 941].
37. Hoffman J.P., Lispitz S., Pisansky T., Weese J.L., Solin L., Benson A.B. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group. J. Clin. Oncol. 16(1):1998;317-323.
38. Wolff R.A., Evans D.B., Crane C.H.et al. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;130. [abstract 516].
39. Sasson A.R., Wetherington R.W., Hoffman J.P.et al. Neoadjuvant therapy for adenocarcinoma of the pancreas: histopathologic effect and analysis of outcome. Proc. Am. Soc. Clin. Oncol. 20:2001;156a. [abstract 621].
40. Cullinan S., Moertel C.G., Wieand H.S.et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 65:1990;220-224.
41. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
42. Todd K.E., Gloor B., Lane J.S., Isacoff W.H., Reber H.A. Resection of locally advanced pancreatic cancer. after downstaging with continuous infusion 5FU, mitomycin and dipyridamole. J. Gastrointest. Surg. 2:1998;159-166.
43. Andre T., Lotz J., Bouleuc C.et al. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann. Oncol. 7:1996;173-178.
44. Rougier P., Ducreux M., Douillard J.et al. Efficacy of 5FU + cisplatin compared to bolus 5FU in advanced pancreatic carcinoma: a randomized trial from the French Anticancer Digestive Group. Proc. Am. Soc. Clin. Oncol. 18:1999;274a. [abstract 1114].
45. Rougier P., Ducreux M., Ould Kaci M.et al. Randomized phase II study of oxaliplatin alone (OXA), 5fluorouracil (5FU) alone and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC). Proc. Am. Soc. Clin. Oncol. 9:2000;262a. [abstract 1018].
46. Wils J.A. Chemotherapy in pancreatic cancer: a rational pursuit? Anticancer Drugs. 2(1):1991;3-10.
47. Moertel C.G., Frytak S., Hahn R.G.et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5FU), and high dose radiation + 5FU: the Gastrointestinal Tumor Study Group. Cancer. 48(8):1981;1705-1710.
48. Loehrer P.J. Sr., Williams S.D., Einhorn L.H., Ansari R. Ifosfamide: an active drug in treatment of adenocarcinoma of pancreas. J. Clin. Oncol. 3:1985;367-373.
49. Ajani J.A., Abbruzzese J.L., Goudeau P.et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J. Clin. Oncol. 6:1988;1703-1709.
50. Hubbard K.P., Pazdur R., Ajani J.A.et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am. J. Clin. Oncol. 15:1992;524.
51. Shimoto G.M., Kuo S., Wade J.et al. Phase II study of trimetrexate glucoronate in the treatment of advanced cancer of the pancreas. Proc. Am. Soc. Clin. Oncol. 11:1992;184.
52. Casper E.S., Schwartz G.K., Johnson B., Kelsen D.P. Phase II trial of edatrexate in patients with advanced pancreatic cancer. Invest New Drugs. 10:1992;313-316.
53. Bukowski R.M., Wolf M., Kulander B.G., Montie J., Crawford E.D., Blumenstein B. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: a Southwest Oncology Group Study. Cancer. 71:1993;322-326.
54. Linke K., Pazdur R., Abbruzzese J.et al. Phase II trial of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 9:1991;353-358.
55. Hansen R., Quebbeman E., Ritch P., Chitambar C., Anderson T. Continuous 5FU infusion in carcinoma of the pancreas: a phase II study. Am. J. Med. Sci. 295:1988;91-93.
56. Mallinson C.N., Rake M.O., Cocking J.B.et al. Chemotherapy in pancreatic cancer: results from a controlled, prospective, randomized, multicenter trial. Br. Med. J. 281:1980;1589-1591.
57. Palmer K.R., Kerr M., Knowles G., Cull A., Crater D.C., Leonard C.F. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. 81:1994;882-885.
58. Tempero M., Plumkett W., Ruiz Van Haperen V.et al. Randomized phase II trial of dose intense gemcitabine by standard infusion versus fixed dose rate in metastatic pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 18:1999;273a. [abstract 1048].
59. Casper E., Green M., Kelsen D. Phase II trial of gemcitabine (2,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 12:1994;29-34.
60. Carmichael J., Fink U., Russel R.C.G.et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer. 73:1996;101-1205.
61. Ulrich-Pur H., Kornek G.V., Raderer M.et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer. 88:2000;2505-2511.
62. Blackstock A.W., Tempero M.A., Niedwiecki D., Hollis D.R., Mayer R.J., Tepper J.E. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 20:2001;158a. [abstract 627].
63. Mustacchi G., Beorchia A., Milani S.et al. Gemcitabine and concomitant radiation for locally advanced relapsed pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;134b. [abstract 2288].
64. Burris H.A. 3rd, Moore M., Anderson J.et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15:1997;2403-2413.
65. Crane C.H., Abbruzzese J.L., Evans D.B.et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5FU-based chemoradiation in locally advanced pancreatic cancer? Int. J. Radiat. Oncol. Biol. Phys. 52(5):2002;1293-1302.
66. Berlin J., Catalano P., Thomas J., Kluger J., Haller D.G., Nenson A.B. A phase III study of gemcitabine in combination with 5FU versus gemcitabine alone in patients with advanced pancreatic carcinoma: an Eastern Cooperative Oncology Group (ECOG) trial. Proc. Am. Soc. Clin. Oncol. 20:2001;127a. [abstract 505].
67. Cascinu S., Silva R., Barni S.et al. A combination of gemcitabine and 5FU in advanced pancreatic cancer, a report from the Italian Group of Digestive Tract Cancer (GISCAD). Br. J. Cancer. 80(10):1999;1595-1598.
68. De Gusmao C.B.R.A., Murad A.M., Scalabrini-Neto A.O.et al. Phase II trial of the use of gemcitabine and 5FU in the treatment of advanced pancreatic cancer and biliary tract adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 17:1998;290a. [abstract 1116].
69. Oettle H., Pelzer U., Hochmuth K.et al. Phase I trial of gemcitabine in combination with 5FU (24 h) and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs. 10:1999;699-704.
70. Oettle H., Arning M., Pelzer U.et al. A phase II trial of gemcitabine in combination with 5FU (24 h) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann. Oncol. 11(10):2000;1267-1272.
71. Polyzos A., Tsavaris N., Kosmas C.et al. A phase II study of gemcitabine plus 5FU modulated by leucovorin (LV) for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;311a. [abstract 1229].
72. Louvet C., Hammel P., Andrè T.et al. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM regimen). Proc. Am. Soc. Clin. Oncol. 18:1999;280a. [abstract 1054].
73. Gutzler F., Moehler M., Hosch W.P.et al. A phase I study of gemcitabine (GEM) in combination with 5 days 5-Fluorouracil (5FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas and bile duct. Proc. Am. Soc. Clin. Oncol. 18:1999;286a. [abstract 1097].
74. Castellano D., Paz-Ares L., Pronk L.et al. A phase I/II clinical and pharmacological study of dose-escalating and dose-sequencing of administration of gemcitabine and folinic acid (FA)/fluorouracil (FU) and leucovorin (LV) in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;290a. [abstract 1133].
75. Borner M.M., Maurer C.A., Friess H.et al. Gemcitabine and continuous infusion fluorouracil: a phase II study in advanced pancreatic cancer. Ann. Oncol. 9(suppl 4):1998;51. [abstract 241P].
76. Hidalgo M., Castellano D., Paz-Ares L.et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol. 17:1999;585-592.
77. Anchisi S., Delaloye B., Petite G.et al. Gemcitabine and continuous infusion 5FU is active and well tolerated in advanced or metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;326a. [abstract 1280].
78. Rodriquez-Lescure A., Carrato A., Massuti B.et al. Phase I-II study of gemcitabine (GEM) and weekly 48 h continuous intravenous infusion (CIV) 5-fluorouracil (5FU) in advanced pancreatic cancer (PC). A University of Chicago Phase II Consortium Study. Proc. Am. Soc. Clin. Oncol. 19:2000;288a. [abstract 1145].
79. Raderer M., Kornek G.V., Valencak J.et al. Phase II trial of gemcitabine, epirubicin, and G-CSF in patients with metastatic pancreatic cancer. Ann. Oncol. 9(suppl 2):1998;169. [abstract 648].
80. Heinemann V., Wilke H., Possinger K.et al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study. Proc. Am. Soc. Clin. Oncol. 18:1999;330. [abstract 1052].
81. Colucci G., Riccardi F., Giuliani F.et al. Randomized trial of Gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): a phase II multicenter study of the Southern Italy Oncology Group. Proc. Am. Soc. Clin. Oncol. 18:1999;252. [abstract 961].
82. Heinemann V., Quietzsch D., Gieseler F.et al. Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: preliminary results of a randomized phase III trial. Proc. Am. Soc. Clin. Oncol. 20:2001;157a. [abstract 625].
83. Philip P.A., Shields A., Zalupski M.et al. Gemcitabine, cisplatin and 5-Fluorourcil in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;148b. [abstract 2341].
84. Kozuch P., Areneo M., Homel P.et al. Biweekly sequential gemcitabine, 5FU (5-Fluorourcil), LV (Leucovorin), and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc. Am. Soc. Clin. Oncol. 20:2001;155a. [abstract 617].
85. Reni M., Passoni P., Panucci M.G.et al. Definitive results of a phase II trial of Cisplatin, Epirubicin, continuous infusion 5-Fluorouracil, and Gemcitabine in stage IV pancreatic adenocarcinoma. J. Clin. Oncol. 19:2001;2679-2686.
86. Garnier C., Rebischung C., Chirpaz E.et al. Phase II study of combination with leucovorin (LV), 5FU bolus and infusion (FU), Gemcitabine (GEM) and Oxaliplatin (LOHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc. Am. Soc. Clin. Oncol. 20:2001;156a. [abstract 620].
87. Louvet C., Andrè T., Lledo G.et al. Gemcitabine-Oxaliplatin (GEMOX regimen) in advanced pancreatic carcinoma (APC). A Gercor multicenter phase II study. Proc. Am. Soc. Clin. Oncol. 20:2001;127a. [abstract 506].
88. Ridwelski K., Kettner E., Greiner L.et al. Multicenter phase II study of weekly docetaxel and gemcitabine for the treatment of patients with advanced or recurrent pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;157a. [abstract 624].
89. Shepard R.C., Levy D., Stuart K.et al. Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy. Proc. Am. Soc. Clin. Oncol. 20:2001;154a. [abstract 614].
90. Lutz M.P., Ducreux M., Wagener T.et al. Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc. Am. Soc. Clin. Oncol. 21:2002;125a. [abstract 498].
91. Bruckner H., Barzdins A., Homel P.et al. Irinotecan combined with gemcitabine, 5FU (5-Fluorouracil), LV (Leucovorin), and Cisplatin (G-FLIP) is an effective and non-cross resistant regimen for refractory metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc. Am. Soc. Clin. Oncol. 20:2001;155a. [abstract 615].
92. Alfonso P.G., Sancho J., Mendez M.et al. A phase II study of weekly irinotecan (CPT11) and gemcitabine (GEM) as a first line treatment in locally advanced and metastatic pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;144b. [abstract 2328].
93. Stapthopoulos G., Rigatos G., Kouroussis C.H.et al. Front line treatment with gemcitabine in combination with irinotecan: preliminary results of a multicenter phase II study. Proc. Am. Soc. Clin. Oncol. 19:2000;319a. [abstract 1260].
94. Rocha Lima C.M.S., Savarese D., Bruckner H.et al. Irinotecan plus gemcitabine induces both radiographic and Ca19 9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. 20:2002;1182-1191.
95. Campos L.T., Alvarez R., Sanford D.et al. Gemcitabine (GEM) and Capecitabine (CPC) in advanced pancreatic cancer and solid tumors. A single institution experience. Proc. Am. Soc. Clin. Oncol. 20:2001;141b. [abstract 2315].
96. Cartwright T.H., Cohn A., Varkey J.A.et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 20(1):2002;160-164.
97. Herrmann R., Borner M., Morant R., Roth A.D., Ludwig C., Bedoucha V. Combining gemcitabine and capecitabine in advanced pancreatic cancer. Results of a phase I trial. Proc. Am. Soc. Clin. Oncol. 19:2000;267a. [abstract 1038].
98. Scheithauer W., Schull B., Ulrich-Pur H.et al. Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 21:2002;126a. [abstract 500].
99. Ueno H., Okada S., Okusaka T., Ikeda M., Kuriyama H. Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology. 62(3):2002;223-227.
100. Feliu J., Mel R., Borrega P.et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann. Oncol. 13(11):2002;1756-1762.
101. Fernadez-Morales L.A., Pujadas J., Garcia Y.et al. Combination of oral tegafur (TF) and levofolinic acid (LA) with gemcitabine (gem) in locally advanced or metastatic pancreatic carcinoma: a pilot study. Proc. Am. Soc. Clin. Oncol. 21:2002;137b. [abstract 2362].
102. Pazdur R., Meropol N.J., Casper E.S.et al. Phase II trial of ZD1694 (Tomudex) on patients with advanced pancreatic cancer. Invest New Drugs. 13:1996;355-358.
103. Miller K.D., Picus J., Blanke C.et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol. 11(1):2000;101-103.
104. Kralidis E., Aebi S., Friess H., Buchler M.W., Borner M.M. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann. Oncol. 14(4):2003;574-579.
105. Kindler H.L., Dugan W., Hochster H.et al. Clinical outcomes in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc. Am. Soc. Clin. Oncol. 21:2002;125a. [abstract 499].
106. Lapointe R., Letourneau R., Steward W.et al. Phase 2 study of troxacitabine in chemotherapy naive patients with advanced cancer of the pancreas. Proc. Am. Soc. Clin. Oncol. 21:2002;142a. [abstract 565].
107. Scher R., Kosierowski R., Lush C.et al. Phase III trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs. 13:1996;347-354.
108. Wagener D.J., Verdonk H.E., Dirix L.Y.et al. Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol. 6:1995;129-132.
109. Bleiberg H. CPT11 in gastrointestinal cancer. Eur. J. Cancer. 35:1999;371-379.
110. Moore M.J., Feld R., Hedley D., Oza A., Siu L.L. A phase II study of temozolomide in advanced untreated pancreatic cancer. Invest New Drugs. 16:1998;77-79.
111. Yip D., Halford S., Karapetis C.S.et al. A phase II study evaluating the tolerability and efficacy of Caelix (Liposomal ADM, Doxil) in the treatment of unresectable pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;301a. [abstract 1182].
112. Whitehead R.P., Jacobson J., Brown T.D., Taylor S.A., Weiss G.R., Macdonald J.S. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic cancer: a Southwest Oncology Group Study. J. Clin. Oncol. 15:1997;2414-2419.
113. Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Invest New Drugs. suppl 6(4):1995;25-29.
114. Rougier P., Adenis A., Ducreux M.et al. A phase II study: docetaxel as first line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer. 36:2000;1016-1025.
115. Androulakis N., Koukourakis C., Dimopoulos M.et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J. Clin. Oncol. 17(6):1999;1779-1785.
116. Safran H., King T.P., Choy H.et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer and gastric cancer: a phase I study. J. Clin. Oncol. 15:1997;901-907.
117. Burtness B., Argiris A., Rich R.S.et al. Weekly chemotherapy with irinotecan plus taxanes in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;277a. [abstract 1081].
118. Kurtz J, Husseini F, Negrier S, et al. Docetaxel and irinotecan combination chemotherapy in advanced pancreatic cancer. A phase II study. Proc Am Soc Clin Oncol 2001;141b [abstract 2313].
119. Conroy T., Paillot B., Francois E.et al. Irinotecan (CPT11), oxaliplatin (L-OHP) plus 5FU/leucovorin (5FU/LV) as first line chemotherapy in patients with advanced pancreatic adenocarcinoma (APA). Proc. Am. Soc. Clin. Oncol. 21:2002;147a. [abstract 585].
120. Cantore M., Rabbi C., Cavazzini G.et al. Irinotecan and oxaliplatin combination therapy in patients with advanced pretreated pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;96b. [abstract 2197].
121. Zervos E.E., Shafii A.E., Rosemurgy A.S. Matrix metalloproteinase inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J. Surg. Res. 81:1999;65-68.
122. Zervos E.E., Shafii A.E., Haq M., Rosemurgy A.S. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J. Surg. Res. 84(2):1999;162-167.
123. Rosemurgy A.S., Serafini F.M. New directions in systemic therapy of pancreatic cancer. Cancer Control. 7(5):2000;437-444.
124. Rosemurgy A., Harris J., Langleben A., Casper E., Goode S., Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. 22:1999;247-252.
125. Zervos E.E., Norman J.G., Gower W.R., Franz M.G., Rosemurgy A.S. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J. Surg. Res. 69(2):1997;367-371.
126. Haq M., Shafii A., Zervos E.E., Rosemurgy A.S. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 60(12):2000;3207-3211.
127. Abbruzzese J.L., Rosenberg A., Xiong Q.et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;130a. [abstract 518].
128. Safran H., Ramanathan R., Schwartz J.et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress Her-2/neu. Proc. Am. Soc. Clin. Oncol. 20:2001;130a. [abstract 517].
129. Slichenmyer W.J., Fry D.W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin. Oncol. 28(Suppl 16):2001;67-79.
130. Rowinsky E., Winde J., Von Hoff D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17:1999;3631-3652.
131. Lersch C., Van Cutsem E., Amado R.et al. Randomized phase II trial of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 20:2001;153a. [abstract 609].
132. Van Cutsem E., Karasek H., Oettle H.et al. Phase III trial comparing gemcitabine R115777 (Zarnestra) versus gemcitabine placebo in advanced pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 21:2002;130a. [abstract 517].
133. Ryan D.P., Eder J.P., Winkelmann J.et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21:2002;95a. [abstract 379].
134. Xiong H.Q., Du M., Wolff R.A.et al. Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;113a. [abstract 448].
135. Ferry D.R., Deakin M., Baddeley J.et al. A phase II study of 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann. Oncol. 11:2000;1165-1170.
136. Gilliam A.D., Henwood M., Watson S.A., Rowlands B., Broome P., Beckingham I. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;134a. [abstract 533].
137. Glimelius B., Hoffman K., Sjoden P.O.et al. Chemotherapy improves quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 7:1996;593-600.